→
Merck presents a profile of both growth potential and challenges in a competitive pharmaceutical landscape.
Merck & Co., Inc. has a market capitalization of $328.69B, with a current stock price of $131.11, reflecting a day range of $130.29 to $131.71. The company has a price-to-earnings (P/E) ratio of 18.01 and a year-over-year earnings per share (EPS) growth of 8.01%. The dividend yield stands at 2.49%, and the return on equity (ROE) is at 34.70%. Revenue growth year-over-year is 1.31%.
Some investors cite Merck's strong return on equity at 34.70% and a solid dividend yield of 2.49% as indicators of financial health. The recent expansion of HIV prevention access with Alimatravir licensing across 129 countries potentially opens new revenue streams.
Concerns exist regarding Merck's revenue growth rate of only 1.31% year-over-year, which may indicate stagnation in its core business. Additionally, the stock may be viewed as 4% undervalued, raising questions about its premium valuation amidst competitive pressures.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly. Free to start. Pro unlocks the full terminal at $20/mo.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Watch my tickers
Get an email when something changes on your tickers: the exact quote, dated and sourced. No account, no brokerage connection, unsubscribe anytime.
Merck & Co., Inc. has a market capitalization of $328.69B, with a current stock price of $131.11, reflecting a day range of $130.29 to $131.71. The company has a price-to-earnings (P/E) ratio of 18.01 and a year-over-year earnings per share (EPS) growth of 8.01%. The dividend yield stands at 2.49%, and the return on equity (ROE) is at 34.70%. Revenue growth year-over-year is 1.31%.
Concerns exist regarding Merck's revenue growth rate of only 1.31% year-over-year, which may indicate stagnation in its core business. Additionally, the stock may be viewed as 4% undervalued, raising questions about its premium valuation amidst competitive pressures.
Some investors cite Merck's strong return on equity at 34.70% and a solid dividend yield of 2.49% as indicators of financial health. The recent expansion of HIV prevention access with Alimatravir licensing across 129 countries potentially opens new revenue streams.
Some investors cite Merck's strong return on equity at 34.70% and a solid dividend yield of 2.49% as indicators of financial health. The recent expansion of HIV prevention access with Alimatravir licensing across 129 countries potentially opens new revenue streams. Concerns exist regarding Merck's revenue growth rate of only 1.31% year-over-year, which may indicate stagnation in its core business. Additionally, the stock may be viewed as 4% undervalued, raising questions about its premium valuation amidst competitive pressures.
Merck & Co., Inc. has a market capitalization of $328.69B, with a current stock price of $131.11, reflecting a day range of $130.29 to $131.71. The company has a price-to-earnings (P/E) ratio of 18.01 and a year-over-year earnings per share (EPS) growth of 8.01%. The dividend yield stands at 2.49%, and the return on equity (ROE) is at 34.70%. Revenue growth year-over-year is 1.31%.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for MRK at helmterminal.dev/analyze/MRK, updated continuously during US market hours. No signup required.